Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to treat type 2 diabetes. Novo's drugs Ozempic and Wegovy are household names ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

"Don't risk your health trying to get healthy," she said. Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that patients are aware that Novo ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 drugs like Wegovy and Zepbound. To catch full episodes of all The Motley Fool's free podcasts, check out our ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...